Boston Scientific (BSX) stock trades down, here is why
Boston Scientific's stock has fallen 40% from its 52-week high despite positive clinical trial results for its Watchman device. Wall Street analysts maintain a strong buy consensus, with price targets ranging from $83 to $124, citing the company's growth potential and undervalued shares.
Boston Scientific's stock currently trades at $64.73, down 40% from its 52-week high. The company presented positive clinical trial results for its Watchman device at the American College of Cardiology conference. The trial met its primary endpoint and demonstrated superiority on bleeding outcomes. RBC Capital expects the results to drive increased focus on the device. The company has demonstrated strong momentum with 19.87% revenue growth over the last twelve months. Analysts have mixed outlooks, with some optimism about the company's growth potential despite competitive challenges.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.